Amicus Therapeutics Stock Forecast, Price & News

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FOLD stock has increased by 179.9% and is now trading at $22.53.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amicus Therapeutics.

Wall Street analysts have given Amicus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amicus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Amicus Therapeutics.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.03. Amicus Therapeutics had a negative net margin of 129.10% and a negative return on equity of 65.53%.
View Amicus Therapeutics' earnings history.

Amicus Therapeutics updated its FY 2020 Pre-Market earnings guidance on Thursday, November, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $256.88 million.

10 brokerages have issued 1-year price objectives for Amicus Therapeutics' stock. Their forecasts range from $12.50 to $31.00. On average, they anticipate Amicus Therapeutics' share price to reach $21.35 in the next year. This suggests that the stock has a possible downside of 5.2%.
View analysts' price targets for Amicus Therapeutics.

Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.64%), BlackRock Inc. (8.10%), Morgan Stanley (4.26%), State Street Corp (3.45%), Jennison Associates LLC (2.07%) and Victory Capital Management Inc. (1.48%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics.

FOLD stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Sphera Funds Management LTD., Phoenix Holdings Ltd., Ardsley Advisory Partners LP, Los Angeles Capital Management & Equity Research Inc., Wells Fargo & Company MN, and Perceptive Advisors LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics.

FOLD stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Asset Management Americas Inc., William Blair Investment Management LLC, Point72 Asset Management L.P., Castleark Management LLC, BNP Paribas Arbitrage SA, Victory Capital Management Inc., and Jennison Associates LLC.
View insider buying and selling activity for Amicus Therapeutics.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FOLD stock can currently be purchased for approximately $22.53.

Amicus Therapeutics has a market capitalization of $5.87 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Amicus Therapeutics employs 584 workers across the globe.

The official website for Amicus Therapeutics is www.amicusrx.com.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]